Mazdutide vs Survodutide
Two GLP-1/glucagon dual agonists compared.
| Attribute | Mazdutide IBI362, GLP-1/Glucagon dual agonist | Survodutide GLP-1/Glucagon dual agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | GLP-1/glucagon dual agonist weight-loss research | Dual-agonist metabolic research |
| In plain English | GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone. | Like tirzepatide, but the second receptor it targets is glucagon — which boosts energy expenditure and fat oxidation. |
| How it works | Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis). | Activates GLP-1 (appetite, insulin) and glucagon (energy expenditure, fat oxidation) receptors. |
| Researchers study | Obesity and metabolic-associated liver disease, particularly in Chinese clinical research. | Obesity, NASH/MASH, and metabolic syndrome. |
| Internet discussion | Discussed alongside survodutide and retatrutide in next-gen metabolic research. | Discussed alongside retatrutide as next-gen weight loss research. |
Mazdutide
GLP-1/glucagon dual agonist weight-loss research
GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone.
Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
Obesity and metabolic-associated liver disease, particularly in Chinese clinical research.
Discussed alongside survodutide and retatrutide in next-gen metabolic research.
Mazdutide is a GLP-1/glucagon dual agonist researched for obesity and metabolic disease.
Survodutide
Dual-agonist metabolic research
Like tirzepatide, but the second receptor it targets is glucagon — which boosts energy expenditure and fat oxidation.
Activates GLP-1 (appetite, insulin) and glucagon (energy expenditure, fat oxidation) receptors.
Obesity, NASH/MASH, and metabolic syndrome.
Discussed alongside retatrutide as next-gen weight loss research.
Survodutide is a dual GLP-1/Glucagon agonist researched for weight and liver outcomes.